Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Androgen receptor (AR) is prevalent in breast cancer (BC) subtypes.
• AR's role in HER2-positive (HER2+) BC remains unclear.
• HER2+ BC requires novel therapeutic strategies.

Purpose of the Study:

• To investigate the function of AR in HER2+ BC.
• To evaluate the efficacy of AR inhibition on HER2+ BC cell growth.
• To explore the therapeutic potential of anti-androgen drugs in HER2+ BC.

Main Methods:

• Knockdown of AR using shRNAs.
• Treatment with Enzalutamide, a novel anti-androgen drug.
• In vitro cell growth assays and in vivo xenograft models.
• Biochemical analysis of signaling pathways (HER2, Erk, Akt).

Main Results:

• AR inhibition (shRNA or Enzalutamide) significantly reduced HER2+ BC cell proliferation.
• Enzalutamide demonstrated efficacy comparable to trastuzumab in vitro and in vivo.
• Combination therapy of Enzalutamide and trastuzumab enhanced growth inhibition.
• AR inhibition decreased HER2 phosphorylation and downstream signaling (Erk, Akt).
• Enzalutamide treatment reduced tumor cell proliferation (Ki67) and increased apoptosis (caspase-3) in vivo.

Conclusions:

• AR plays a critical role in promoting HER2+ BC growth through cross-talk with HER2 signaling.
• Enzalutamide shows significant anti-tumor activity in HER2+ BC models.
• Anti-androgen therapy represents a potential alternative or supplementary treatment for HER2+ BC.